Skip to main content

Advertisement

Table 6 Incremental cost-effectiveness of 10- valent pneumococcal conjugate vaccine in terms of prevented ALRI incidence/1000-person years during three years follow-up from inclusion in the study in the intervention group, vaccinated sub-group (Sep. 2011 – Aug. 2012) and control group (Sep. 2009 – Aug. 2010) at Butajira rural health program site

From: Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation

Health outcomes Cost* Incremental cost Effectiveness Incremental effectiveness Incremental cost- effectiveness ratio (ICER)
  No discounting Discounting 3%
Incidence of ALRI/1000-person years
  < 1 year of age
  Intervention 36.35 29.7 154.6 −46.6 Dominated Dominated
  Vaccinated 34.0 27.39 154.5 −46.5 Dominated Dominated
  Control 6.6   108.0    
  > 1 year of age
  Intervention 29.3 26.4 56.4 3.96 6.7 7.5
  Vaccinated 28.7 25.9 30.6 29.8 0.9 1.0
  Control 2.83   60.4    
  > 2 years of age
  Intervention 28.3 25.8 26.1 3.5 7.3 9.7
  Vaccinated 28.7 26.2 22.8 6.8 0.26 3.1
  Control 2.5   29.6    
 Total follow-up period 27      
  Intervention 39.7 28.1 88.5 −13.3 Dominated Dominated
  Vaccinated 39.5 .9 82.1 −7.0 Dominated Dominated
  Control 11.6   75.2